Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dimitrios Tsamis

Dimitrios Tsamis

Athens Medical Center, Greece

Title: Cytokine’s levels after laparoscopic and open colectomies for cancer: A matched case control study

Biography

Biography: Dimitrios Tsamis

Abstract

Studies dealing with laparoscopic colectomy for cancer have reached to conflicting results in regards to various inflammatory cytokines. The aim of this study was to detect differences of proinflammatory cytokines between conventional and laparoscopic colectomy for cancer.

30 patients who underwent laparoscopic colectomy were with 30 patients treated by “open” surgery. CRP, IL -1, -6, -8 and IFN-γ serum levels were measured preoperatively, at 24 hrs and at the 7th POD.

CRP and IL-6 postop values (24 h and 7th POD) were significantly higher than baseline at both groups (p=0.001), but the respective values at the 7th POD were less than at 24 h (p=0.001). IL-1 and -8 levels did not show any differences. A higher INF-γ measurement was demonstrated at 24 h compared to baseline at the laparoscopic group only (p=0.05). This difference was not maintained at the 7th POD. Relative differences at cytokines concentration showed that INF-γ increment noted at the laparoscopic group was more accentuated than the respective IL-1 value changes (p=0.09 and p=0.024, respectively). INF-γ levels at 24 h and the 7th POD were significantly less at the “open” compared to the laparoscopic group of patients (p=0.001).

This matched case-control study verifies the already reported lack of differences regarding the IL-1. Controversy still exists on likely IL-6 differences. IL-8 does not seem to play an important role on immunologic differences. INF-γ seems to have a more active presence following the laparoscopic colectomies potentially contributing to an immunologic “advantage” by counteracting “harmful” cytokines, such as IL-1.